7Baggers

Equillium, Inc
(NASDAQ:EQ) 

EQ stock logo

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune ...

Founded: 2017
Full Time Employees: 26
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 
                                   
      operating expenses:
    		                               
      research and development
    		5,924,000 1,536,000 1,301,000 4,083,000 9,743,000 7,315,000 9,562,000 10,808,000 9,272,000 9,184,000 8,974,000 9,610,000 10,763,000 8,525,000 8,771,000 9,488,000 10,763,000 7,549,000 6,965,000 5,985,000 5,880,000 6,567,000 4,218,000 3,893,000 4,706,000 5,449,000 4,182,000 4,250,000 3,759,000 2,517,936 1,222,296 
      general and administrative
    		2,946,000 2,426,000 3,274,000 2,145,000 3,737,000 1,775,000 3,278,000 3,145,000 3,715,000 3,227,000 3,519,000 3,105,000 3,517,000 5,192,000 4,466,000 4,064,000 3,517,000 2,838,000 2,896,000 2,858,000 2,815,000 2,403,000 2,298,000 2,717,000 2,746,000 2,167,000 2,142,000 2,189,000 2,589,000 1,710,162 1,003,584 
      total operating expenses
    		8,870,000 3,962,000 4,575,000 6,228,000 13,480,000 9,090,000 12,840,000 13,953,000 12,987,000 12,411,000 12,493,000 12,715,000 37,329,000 13,717,000 13,237,000 13,552,000 37,329,000 10,387,000 9,861,000 8,843,000 8,695,000 8,970,000 6,516,000 6,610,000 7,452,000 7,616,000 6,324,000 6,439,000 6,348,000 4,228,098 2,225,880 
      income from operations
    		-8,870,000 -3,962,000 -4,575,000 -6,228,000 -2,791,000 -4,698,000 -679,000 -100,000 -4,108,000 -3,200,000 -3,623,000 -3,591,000 -37,329,000 2,042,000 -13,237,000 -13,552,000 -37,329,000 -10,387,000 -9,861,000 -8,843,000 -8,695,000 -8,970,000 -6,516,000 -6,610,000 -7,452,000 -7,616,000 -6,324,000 -6,439,000 -6,348,000 -4,228,098 -2,225,880 
      yoy
    		217.81% -15.67% 573.78% 6128.00% -32.06% 46.81% -81.26% -97.22% -89.00% -256.71% -72.63% -73.50% 0.00% -119.66% 34.24% 53.25% 329.32% 15.80% 51.34% 33.78% 16.68% 17.78% 3.04% 2.66% 17.39% 80.13% 184.11%     
      qoq
    		123.88% -13.40% -26.54% 123.15% -40.59% 591.90% 579.00% -97.57% 28.37% -11.68% 0.89% -90.38% -1928.06% -115.43% -2.32% -63.70% 259.38% 5.33% 11.51% 1.70% -3.07% 37.66% -1.42% -11.30% -2.15% 20.43% -1.79% 1.43% 50.14% 89.95%  
      operating margin %
    		-Infinity% -Infinity% -Infinity% -Infinity% -26.11% -106.97% -5.58% -0.72% -46.27% -34.74% -40.85% -39.36% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 
      other income, net:
    		                               
      interest income
    		173,000 303,000 235,000 122,000 439,000 239,000 331,000 371,000 639,000 517,000 551,000 627,000 25,000 201,000 130,000 64,000 25,000 10,000 8,000 13,000 26,000 53,000 81,000 122,000 220,000 294,000 324,000 375,000 398,000 -282,150 -27,544 
      other income
    		43,000 -116,000 110,000 367,000 -382,000 39,000 341,000 197,000     142,000    142,000 22,000 -163,000 -58,000  275,000 114,000 301,000        
      total other income
    		216,000 187,000 345,000 489,000 57,000 -735,000 672,000 568,000 228,000 874,000 409,000 256,000 -88,000       -315,000  52,000 -81,000 149,000 -385,000 49,000 310,000 370,000 398,000   
      net income
    		-8,654,000 -3,775,000 -4,230,000 -5,739,000 -2,734,000 -5,794,000 -7,000 468,000 -3,940,000 -2,342,000 -3,710,000 -3,343,000 -37,417,000 2,773,000 -13,655,000 -14,129,000 -37,417,000 -10,621,000 -10,282,000 -9,158,000 -8,991,000 -8,918,000 -6,597,000 -6,461,000 -7,837,000 -7,567,000 -6,014,000 -6,069,000 -5,950,000   
      yoy
    		216.53% -34.85% 60328.57% -1326.28% -30.61% 147.40% -99.81% -114.00% -89.47% -184.46% -72.83% -76.34% 0.00% -126.11% 32.80% 54.28% 316.16% 19.10% 55.86% 41.74% 14.73% 17.85% 9.69% 6.46% 31.71%       
      qoq
    		129.25% -10.76% -26.29% 109.91% -52.81% 82671.43% -101.50% -111.88% 68.23% -36.87% 10.98% -91.07% -1449.33% -120.31% -3.35% -62.24% 252.29% 3.30% 12.27% 1.86% 0.82% 35.18% 2.10% -17.56% 3.57% 25.82% -0.91% 2.00%    
      net income margin %
    		-Infinity% -Infinity% -Infinity% -Infinity% -25.58% -131.92% -0.06% 3.38% -44.37% -25.43% -41.83% -36.64% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% 
      other comprehensive gain, net:
    		                               
      unrealized loss on available-for-sale securities
    		-3,000    -22,000           -54,000 -180,000 -48,000 -3,000             
      foreign currency translation gain
    		-47,000   -346,000 305,000 793,000 -275,000 -166,000 133,000 -348,000 99,000 71,000 -136,000 -244,000 273,000 359,000 -136,000 -24,000 146,000 51,000 45,000 -12,000 -56,000 -308,000 315,000 1,500 7,000     
      total other comprehensive gain
    		-50,000                               
      comprehensive loss
    		-8,704,000 -3,682,000 -4,345,000 -6,085,000 -2,451,000 -5,010,000 -261,000  -3,711,000 -2,660,000 -3,592,000 -3,308,000 -37,733,000 2,656,000 -13,313,000 -13,824,000 -37,733,000 -10,693,000 -10,139,000 -9,112,000 -8,949,000 -9,186,000 -6,724,000 -6,838,000 -7,384,000 -7,626,000 -6,021,000 -6,031,000 -5,906,000   
      net income per share
    		-0.24    -0.08 -0.17   -0.11 -0.06 -0.11 -0.1 -1.17 0.1 -0.4 -0.41 -1.17 -0.37 -0.35 -0.31 -0.33 -0.35 -0.31 -0.37 -0.45 -0.43 -0.35 -0.35 -0.34 -0.33 -0.44 
      weighted-average number of common shares outstanding, basic and diluted
    		35,586,861 57,304,181   35,254,752 35,357,641 35,424,388  34,414,149 34,726,384 34,878,700 34,449,769 31,865,783 33,727,945 34,352,084 34,292,642 31,865,783 28,806,310    20,355,534          
      revenue
    		    10,689,000 4,392,000 12,161,000 13,853,000 8,879,000 9,211,000 8,870,000 9,124,000                    
      yoy
    		    20.39% -52.32% 37.10% 51.83%                        
      qoq
    		    143.37% -63.88% -12.21% 56.02% -3.60% 3.84% -2.78%                     
      other comprehensive loss, net:
    		                               
      unrealized gain on available-for-sale securities
    		 -750    -9,000 21,000 -6,000 96,000 30,000 19,000 -36,000 -180,000 -41,250 69,000     -5,000 -3,000 -39,000 -71,000 -69,000 138,000 -25,000 -14,000 39,000 44,000   
      foreign currency translation loss
    		 -127,000 -115,000                         -1,000    
      total other comprehensive loss
    		 -127,750 -115,000                             
      net income per share
    		-0.24    -0.08 -0.17   -0.11 -0.06 -0.11 -0.1 -1.17 0.1 -0.4 -0.41 -1.17 -0.37 -0.35 -0.31 -0.33 -0.35 -0.31 -0.37 -0.45 -0.43 -0.35 -0.35 -0.34 -0.33 -0.44 
      basic
    		 -0.103 -0.06 -0.16    0.01                        
      diluted
    		 -0.103 -0.06 -0.16    0.01                        
      weighted-average number of common shares outstanding:
    		                               
      basic
    		  65,322,753 35,719,317    35,292,035                        
      diluted
    		  65,322,753 35,719,317    36,589,774                        
      other comprehensive income, net:
    		                               
      total other comprehensive income
    		   -346,000 283,000 784,000 -254,000 -172,000 229,000 -318,000 118,000 35,000 -316,000 -117,000 342,000 305,000 -316,000 -72,000 143,000 46,000 42,000 -268,000 -127,000 -377,000 453,000 -59,000 -7,000 38,000    
      interest expense
    		        -232,000   -259,000 -255,000 -271,000 -267,000 -259,000 -255,000 -266,000 -266,000 -270,000 -271,000 -276,000 -276,000 -274,000 -273,000 -277,000 -2,000   228,214 1,221,100 
      income before income taxes
    		     -568,250 -7,000 468,000 -3,880,000 -2,607,250 -3,214,000 -3,335,000 -37,417,000                   
      income tax expense
    		        60,000 16,000 496,000 8,000                    
      comprehensive income
    		       296,000                        
      other expense
    		        -179,000 -108,250 -142,000 -112,000  -130,000 -281,000 -382,000     -51,000    -332,000 -4,250 -12,000 -5,000    
      acquired in-process research and development
    		            23,049,000    23,049,000               
      other expense, net:
    		                               
      total other expense
    		             731,000 -418,000 -577,000 -88,000 -234,000 -421,000  -296,000         763,795 2,690,543 
      weighted-average common shares outstanding, basic and diluted
    		                  29,382,806 29,076,562 27,325,372  21,374,240 17,692,731 17,562,551 17,378,096 17,376,236 17,376,236 17,376,236 12,190,245 11,078,840 
      change in fair value of biocon anti-dilution right
    		                             817,731 1,496,987 
      other comprehensive income:
    		                               
      other expense:
    		                               
      net loss and comprehensive loss
    		                             -2,064,645.5 -4,916,423 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 
                                     
        assets
      		                               
        current assets:
      		                               
        cash and cash equivalents
      		61,322,000 30,277,000 33,120,000 11,495,000 14,502,000 18,085,000 15,448,000 11,057,000 11,568,000 23,216,000 34,382,000 25,624,000 24,503,000 59,107,000 25,729,000 23,808,000 26,244,000 50,366,000 77,155,000 73,525,000 50,861,000 23,982,000 49,249,000 24,083,000 20,614,000 13,219,000 27,657,000 22,661,000 21,394,000 28,508,534 4,982,505 
        prepaid expenses and other current assets
      		953,000 761,000 459,000 457,000 1,714,000 2,403,000 2,760,000 2,695,000 5,147,000 4,748,000 3,836,000 5,235,000 4,804,000 2,874,000 2,254,000 2,920,000 3,262,000 2,659,000 1,476,000 1,923,000 2,536,000 3,011,000 1,623,000 1,572,000 2,147,000 2,288,000 671,000 852,000 1,022,000 1,185,844 77,805 
        total current assets
      		62,275,000 31,038,000 33,579,000 11,952,000 16,216,000 24,978,000 33,646,000 41,887,000 42,480,000 49,349,000 53,911,000 57,356,000 70,220,000 76,735,000 46,776,000 60,482,000 72,085,000 83,370,000 92,170,000 99,566,000 106,615,000 85,174,000 92,160,000 44,178,000 49,822,000 55,431,000 62,909,000 57,796,000 62,629,000 67,099,128 5,060,310 
        operating lease right-of-use assets
      		567,000 658,000 753,000 246,000 280,000 364,000 473,000 592,000 694,000 796,000 922,000 992,000 1,114,000 1,191,000 1,319,000 1,418,000 1,541,000 1,645,000              
        property and equipment
      		214,000 164,000 174,000 201,000 233,000 262,000 293,000 329,000 361,000 315,000 313,000 329,000 360,000 391,000 423,000 451,000 464,000 237,000 243,000 254,000 223,000 239,000 225,000 81,000 89,000 93,000 71,000 77,000 83,000 63,515 31,887 
        other assets
      		27,000 27,000     45,000 53,000 62,000 70,000 79,000 87,000 96,000 104,000 113,000 121,000 145,000 153,000 57,000 17,000  15,000    15,000 15,000 15,000 15,000   
        total assets
      		63,083,000 31,887,000 34,506,000 12,399,000 16,729,000 25,604,000 34,457,000 42,861,000 43,597,000 50,530,000 55,225,000 58,764,000 71,790,000 78,421,000 48,631,000 62,472,000 74,235,000 85,405,000 92,470,000 99,837,000 106,838,000 85,428,000 92,385,000 44,259,000 49,911,000 55,539,000 62,995,000 57,888,000 62,727,000 67,162,643 6,421,547 
        liabilities and stockholders' equity
      		                               
        current liabilities:
      		                               
        accounts payable
      		1,295,000 755,000 1,082,000 4,812,000 3,058,000 2,676,000 3,666,000 4,486,000 2,778,000 4,707,000 3,635,000 3,026,000 5,692,000 3,977,000 2,469,000 5,091,000 4,210,000 1,225,000 2,669,000 1,816,000 2,324,000 2,766,000 1,681,000 1,761,000 1,801,000 1,873,000 2,675,000 1,974,000 1,588,000 1,119,150 1,230,262 
        accrued expenses
      		1,609,000 1,816,000 1,740,000 2,272,000 2,798,000 3,483,000 5,049,000 6,903,000 5,646,000 6,697,000 8,304,000 7,537,000 5,443,000 7,239,000 6,326,000 5,377,000 5,626,000 5,886,000 3,859,000 3,164,000 2,593,000 2,813,000 2,631,000 1,626,000 1,910,000 2,010,000 1,599,000 1,688,000 1,464,000 908,827 1,449,492 
        current portion of operating lease liabilities
      		441,000 363,000 272,000 150,000 146,000 197,000 274,000 350,000 424,000 440,000 428,000 416,000 404,000 408,000 421,000 434,000 420,000 376,000              
        total current liabilities
      		3,345,000 2,934,000 3,094,000 7,234,000 6,002,000 6,356,000 11,057,000 20,169,000 22,208,000 27,573,000 28,199,000 25,218,000 32,020,000 32,038,000 14,930,000 15,188,000 13,113,000 8,915,000 7,778,000 4,980,000 7,417,000 7,245,000 5,145,000 3,387,000 3,711,000 3,883,000 4,274,000 3,662,000 3,052,000 2,027,977 2,679,754 
        long-term operating lease liabilities
      		251,000 356,000 473,000 109,000 149,000 187,000 223,000 259,000 295,000 384,000 498,000 609,000 719,000 824,000 925,000 1,025,000 1,122,000 1,235,000              
        total liabilities
      		3,596,000 3,290,000 3,567,000 7,343,000 6,151,000 6,543,000 11,280,000 20,428,000 22,503,000 27,957,000 31,117,000 31,783,000 42,521,000 46,479,000 20,471,000 22,205,000 21,605,000 18,900,000 16,668,000 15,064,000 14,958,000 15,574,000 14,259,000 13,287,000 13,565,000 13,691,000 14,036,000 3,825,000 3,233,000 2,227,507 16,800,311 
        commitments and contingencies
      		                               
        stockholders' equity:
      		                               
        common stock, 0.0001 par value...
      		5,000 5,000 5,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 2,000 2,000 2,000 2,000 2,000 2,000 1,000 1,000 1,000 1,000 1,000 1,000 789 166 
        additional paid-in capital
      		280,628,000 244,434,000 243,094,000 212,868,000 212,305,000 212,084,000 211,190,000 210,185,000 209,142,000 208,170,000 207,045,000 206,326,000 205,306,000 204,268,000 203,142,000 201,936,000 200,475,000 176,618,000 175,222,000 174,054,000 172,049,000 141,074,000 140,161,000 86,284,000 84,820,000 82,938,000 82,423,000 81,506,000 80,906,000 80,441,417 141,526 
        accumulated other comprehensive income
      		370,000 363,000 270,000 385,000 731,000 781,000 -3,000 251,000 423,000 140,000 458,000 340,000 305,000 76,000 193,000       -297,000 -30,000 97,000 474,000 21,000 80,000 87,000 49,000   
        accumulated deficit
      		-221,516,000 -216,205,000 -212,430,000 -208,200,000 -202,461,000 -193,807,000 -188,013,000 -188,006,000 -188,474,000 -185,740,000 -183,398,000 -179,688,000 -176,345,000 -172,405,000 -175,178,000 -161,523,000 -147,394,000 -109,977,000 -99,356,000 -89,074,000 -79,916,000 -70,925,000 -62,007,000 -55,410,000 -48,949,000 -41,112,000 -33,545,000 -27,531,000 -21,462,000 -15,512,349 -10,520,456 
        total stockholders' equity
      		59,487,000 28,597,000 30,939,000 5,056,000 10,578,000 19,061,000 23,177,000 22,433,000 21,094,000 22,573,000 24,108,000 26,981,000 29,269,000 31,942,000 28,160,000 40,267,000 52,630,000 66,505,000 75,802,000 84,773,000 91,880,000 69,854,000 78,126,000 30,972,000 36,346,000 41,848,000 48,959,000 54,063,000 59,494,000 64,935,136  
        total liabilities and stockholders' equity
      		63,083,000 31,887,000 34,506,000 12,399,000 16,729,000 25,604,000 34,457,000 42,861,000 43,597,000 50,530,000 55,225,000 58,764,000 71,790,000 78,421,000 48,631,000 62,472,000 74,235,000 85,405,000 92,470,000 99,837,000 106,838,000 85,428,000 92,385,000 44,259,000 49,911,000 55,539,000 62,995,000 57,888,000 62,727,000 67,162,643  
        short-term investments
      		     4,490,000 10,429,000 22,242,000 20,717,000 17,650,000 11,924,000 22,754,000 37,489,000 11,916,000 18,793,000 33,754,000 42,579,000 30,345,000 13,539,000 24,118,000 53,218,000 58,181,000 41,288,000 18,523,000 27,061,000 39,924,000 34,581,000 34,283,000 40,213,000 37,404,750  
        accounts receivable
      		      5,009,000 5,893,000 5,048,000 3,735,000 3,769,000 3,743,000 3,424,000 2,838,000                  
        current portion of deferred revenue
      		      2,068,000 8,430,000 13,360,000 15,729,000 15,832,000 14,239,000 14,767,000 14,700,000                  
        current portion of notes payable
      		            5,714,000                   
        long-term notes payable
      		            1,841,000 3,239,000 4,616,000 5,992,000 7,370,000 8,750,000 8,873,000 10,067,000 7,506,000 8,275,000 9,043,000 9,810,000 9,746,000 9,681,000 9,616,000     
        long-term deferred revenue
      		          2,420,000 5,956,000 7,941,000 10,378,000                  
        current portion of long-term notes payable
      		             5,714,000 5,714,000 4,286,000 2,857,000 1,428,000 1,250,000  2,500,000 1,666,000 833,000         
        accumulated other comprehensive loss
      		               -149,000 -454,000 -138,000 -66,000 -209,000 -255,000           
        other non-current liabilities
      		                  17,000 17,000 35,000 54,000 71,000 90,000 108,000 127,000 146,000   199,530 148,724 
        non-current liabilities
      		                           163,000 181,000   
        long-term convertible promissory notes
      		                              10,321,940 
        long-term convertible promissory notes, related party
      		                              1,274,784 
        biocon anti-dilution right
      		                              2,375,109 
        stockholders' equity
      		                               
        accumulated other comprehensive gain
      		                             5,279  
        deferred offering costs
      		                              1,329,350 
        liabilities and stockholders' deficit
      		                               
        stockholders' deficit:
      		                               
        total stockholders' deficit
      		                              -10,378,764 
        total liabilities and stockholders' deficit
      		                              6,421,547 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2018-12-31 
                                    
          operating activities:
        		                            
          net loss
        		-5,311,000 -3,775,000 -4,230,000 -5,739,000 -8,654,000 -5,794,000 -7,000 468,000 -2,734,000 -2,342,000 -3,710,000 -3,343,000 -3,940,000 2,773,000 -13,655,000 -14,129,000 -37,417,000 -10,621,000 -10,282,000 -9,158,000 -8,991,000 -8,918,000 -6,597,000 -6,461,000 -7,837,000 -7,567,000 -6,014,000 -4,991,893 
          adjustments to reconcile net loss to net cash from operating activities:
        		                            
          depreciation
        		24,000 23,000 28,000 32,000 33,000 35,000 35,000 35,000 32,000                    
          stock-based compensation
        		930,000 737,000 401,000 563,000 621,000 821,000 1,005,000 952,000 972,000 1,046,000 979,000 934,000 1,038,000 1,052,000 1,189,000 1,302,000 1,298,000 1,152,000 1,150,000 1,064,000 1,044,000 833,000 847,000 1,350,000 787,000 592,000 633,000 310,559 
          net unrealized loss on foreign currency transactions
        		7,000   -370,000 -49,000 977,000 -342,000 -224,000 383,000 -357,000 145,000 111,000 159,000 -259,000 274,000 385,000 -140,000 -22,000 155,000 57,000 50,000  -119,000 -302,000 336,000    
          amortization of investments
        		 0 0 0 -14,000  -166,000 -241,000 -278,000   -301,000 -296,000                
          changes in operating assets and liabilities:
        		                            
          prepaid expenses and other current assets
        		-192,000 -321,000 8,000 1,273,000 303,000 277,000 -10,000 2,528,000 -520,000 -750,000 1,366,000 -438,000 -1,983,000 -608,000 670,000 333,000 -553,000 -1,271,000 233,000 771,000 481,000 -1,353,000 -28,000 591,000 299,000 -1,610,000 177,000 -1,108,039 
          accounts payable
        		434,000 -33,000 -4,030,000 1,745,000 381,000 -949,000 -843,000 1,756,000 -1,959,000 1,046,000 607,000 -2,656,000 1,726,000 1,498,000 -2,613,000 931,000 2,692,000 -1,474,000 867,000 -482,000 -489,000 1,123,000 -129,000 -61,000 -39,000 -784,000 669,000 490,725 
          accrued expenses
        		-257,000 91,000 -475,000 -515,000 -786,000 -1,534,000 -1,858,000 1,239,000 -1,011,000 -1,710,000 824,000 2,103,000 -1,771,000 908,000 971,000 -229,000 -1,218,000 2,031,000 718,000 570,000 -220,000 181,000 1,005,000 -284,000 -50,000 357,000 -88,000 423,133 
          right-of-use assets and lease liabilities
        		64,000 69,000 -21,000 -2,000 -4,000 -5,000 7,000 -7,000 -4,000 24,000 -29,000 25,000 -33,000 14,000 -13,000              
          net cash from operating activities
        		-4,301,000 -3,133,000 -8,431,000 -3,013,000 -8,169,000 -3,299,000 -7,657,000 730,000 -8,800,000 -5,664,000 -1,909,000 -6,215,000 -7,995,000 27,725,000 -13,065,000 -11,259,000 -12,134,000 -10,133,000 -7,010,000 -6,994,000 -7,944,000 -8,253,000 -4,921,000 -5,080,000 -6,370,000 -9,033,000 -4,696,000 -3,826,968 
          capital expenditures
        		68,000 -44,000 0 0 -4,000 -4,000 0 -62,000 40,000 -35,000 0 0 0 -2,000 0 -54,000 -223,000 0 -34,000 0 0 -30,000 -157,000 0 -15,000 -18,000 0 15,067 
          free cash flows
        		-4,233,000 -3,177,000 -8,431,000 -3,013,000 -8,173,000 -3,303,000 -7,657,000 668,000 -8,760,000 -5,699,000 -1,909,000 -6,215,000 -7,995,000 27,723,000 -13,065,000 -11,313,000 -12,357,000 -10,133,000 -7,044,000 -6,994,000 -7,944,000 -8,283,000 -5,078,000 -5,080,000 -6,385,000 -9,051,000 -4,696,000 -3,811,901 
          investing activities:
        		                            
          purchases of property and equipment
        		-3,000 -44,000 0 0 -4,000 -4,000 0 -62,000 -19,000 -35,000    -2,000 0 -54,000 -223,000 0 -34,000   -30,000 -157,000 0 -15,000 -18,000 0 -9,477 
          maturities of short-term investments
        		 0 0 0 4,500,000 6,000,000 12,000,000 9,000,000 4,500,000 12,000,000 11,000,000 15,000,000 12,000,000 6,980,000 15,000,000 8,745,000 2,500,000 2,500,000 16,500,000 28,990,000 12,465,000 8,190,000 5,230,000 8,455,000 15,245,000 13,212,000 10,240,000  
          net cash from investing activities
        		-3,000 -32,000 0 0 4,496,000 5,996,000 12,000,000 -1,351,000 -2,831,000 -5,566,000 10,985,000 15,000,000 -25,181,000 6,978,000 15,000,000 8,691,000 -11,985,000 -16,889,000 10,468,000 28,967,000 4,860,000 -17,036,000 -23,016,000 8,455,000 13,005,000 -5,330,000 -225,000 -37,408,948 
          financing activities:
        		                            
          proceeds from exercise of stock options
        		448,000 604,000 1,194,000 0 38,000             91,000 174,000 622,000 4,000        
          proceeds from a private placement of common stock and pre-funded warrants, net of issuance costs
        		34,898,000                            
          net cash from financing activities
        		35,346,000 283,000 30,069,000 -16,000 91,000 73,000 0   79,000 -260,000 -7,618,000 -1,429,000 -1,356,000 0   225,000 174,000 698,000 29,964,000 11,000 53,063,000 96,000 775,000 -105,000  64,761,945 
          effect of exchange rate changes on cash and cash equivalents
        		3,000 39,000 -13,000 22,000 -1,000 -133,000 48,000 19,000 -17,000 -15,000 -58,000 -46,000 1,000 31,000 -14,000 -9,000 -3,000 8,000 -2,000 -7,000 -1,000 11,000 40,000 -2,000 -15,000 30,000 -24,000  
          net increase in cash and cash equivalents
        		31,045,000 -2,843,000            33,378,000 1,921,000 -2,436,000 -24,122,000 -26,789,000 3,630,000 22,664,000 26,879,000 -25,267,000 25,166,000 3,469,000 7,395,000    
          cash and cash equivalents at beginning of period
        		30,277,000 0 0 0 18,085,000 0 0 0 23,216,000 0 0 0 59,107,000 0 0 0 50,366,000 0 0 0 23,982,000 0 0 0 13,219,000 0 0 0 
          cash and cash equivalents at end of period
        		61,322,000 -2,843,000 21,625,000 -3,007,000 14,502,000 2,637,000 4,391,000 -511,000 11,568,000 -11,166,000 8,758,000 1,121,000 24,503,000 33,378,000 1,921,000 -2,436,000 26,244,000 -26,789,000 3,630,000 22,664,000 50,861,000 -25,267,000 25,166,000 3,469,000 20,614,000 -14,438,000 4,996,000 23,526,029 
          non-cash investing and financing activities:
        		                            
          private placement issuance costs in accounts payable and accrued expenses
        		81,000                            
          amounts included in accounts payable for purchases of property and equipment
        		71,000        59,000                   24,544 
          exercise of stock options issuance costs in accounts payable and accrued expenses
        		1,000                            
          atm facility issuance costs in accrued expenses
        		   -16,000 99,000                        
          atm facility issuance costs reclassed from other current assets
        		 0 0 0 392,000                        
          loss on disposal of property and equipment
        		                            
          deferred revenue
        		     -2,067,000 -6,363,000 -4,930,000 -2,368,000 -2,523,000 -1,944,000 -2,512,000 -2,370,000                
          accounts receivable
        		     5,009,000 885,000 -846,000 -1,313,000 34,000 -26,000 -319,000 -586,000                
          proceeds from disposal of property and equipment
        		                            
          purchases of short-term investments
        		     0 0 -10,289,000 -7,312,000 -17,531,000 0 0 -37,181,000 0 0 0 -14,962,000 -19,389,000 -5,998,000 0 -7,605,000 -25,196,000 -28,089,000 0 -2,225,000 -18,524,000 -10,465,000  
          proceeds from issuance of common stock under atm facility, net of issuance costs
        		 -137,000 782,000 -16,000 53,000                  17,305,000 0 775,000    
          proceeds from issuance of common stock under employee stock purchase plan
        		     69,000 0   79,000 0                  
          right-of-use assets obtained in exchange for lease obligations
        		 0                           
          exercise of stock options issuance costs in accounts payable
        		                            
          supplemental cash flow information:
        		                            
          cash paid for income taxes, net of refunds
        		                            
          net unrealized gain on foreign currency transactions
        		                            
          proceeds from private placement of equity securities, net of issuance costs
        		                            
          atm facility issuance costs in accounts payable
        		                            
          exercise of stock options issuance costs in accrued expenses
        		                            
          adjustments to reconcile net loss to cash from operating activities:
        		                            
          net decrease in cash and cash equivalents
        		   -3,007,000 -3,583,000 2,637,000 4,391,000 -511,000 -11,648,000  8,758,000 1,121,000 -34,604,000              4,996,000  
          amortization of term loan discount and issuance costs
        		         0 0 150,000 30,000 51,000 52,000 52,000 48,000 55,000 56,000 62,000 64,000 65,000 65,000 65,000 65,000    
          amortization of premium on investments
        		                            
          repayment of notes payable
        		         0 0                  
          common stock repurchased
        		         0                   
          cash paid for interest
        		                            
          cash paid for income taxes
        		                            
          principal repayments on notes payable
        		            -1,429,000                
          acquired in-process research and development
        		             0 0 0 23,049,000            
          amortization of premium and accretion of discounts on investments
        		         -165,000                   
          cash acquired in bioniz acquisition
        		             0 0 0 700,000            
          fair value of bioniz assets acquired
        		             0 0 0 23,049,000            
          issuance of common stock for bioniz acquisition
        		             0 0 0 -22,542,000            
          bioniz net liabilities assumed
        		             0 0 0 507,000            
          depreciation and amortization
        		          31,000 31,000 31,000 32,000 30,000 31,000 25,000 19,000 19,000 17,000 17,000 17,000 13,000 7,000 8,000 6,000 6,000 2,393 
          property and equipment in accounts payable
        		                36,000            
          proceeds from issuance of common stock from follow-on offering, net of issuance costs
        		                            
          proceeds from espp purchases
        		                            
          amortization/accretion of investments
        		              30,000 26,000 47,000    100,000 74,000       
          proceeds from registered direct offering, net of offering costs
        		                 0 0 -51,000 29,960,000        
          proceeds from exercises of stock options
        		                            
          proceeds from employee stock purchase plan purchases
        		              0              
          unsettled stock option exercises
        		                            
          right-of-use assets, operating leases
        		                104,000            
          operating lease liabilities
        		                -69,000            
          supplemental disclosures of non-cash activities:
        		                            
          registered direct offering issuance costs in accounts payable
        		                    50,000        
          non-cash consulting expense
        		                     0 0 0 81,000    
          realized gain on investments
        		                     0 0 0 -13,000    
          proceeds from issuance of common stock under atm, net of issuance costs
        		                            
          issuance of commitment shares to lincoln park pursuant to agreement
        		                     0 0 0 171,000    
          amortization of discount on investments
        		                  74,000          
          proceeds from issuance of common stock, net of issuance costs
        		                            
          proceeds from espp purchase
        		                  0    0      
          equity issuance costs in accounts payable
        		                            
          proceeds from issuance of common stock under atm facilities, net of issuance costs
        		                            
          proceeds from issuance of notes payable, net of issuance costs
        		                         -60,000   
          fair value of common stock warrants in connection with issuance of notes payable
        		                         0   
          atm issuance costs in accrued expenses
        		                            
          notes payable issuance costs in accounts payable
        		                            
          accretion of discount on investments
        		                       15,000 -7,000 -55,000 -86,000  
          deferred rent
        		                           209 
          non-cash interest expense
        		                           228,214 
          change in fair value of biocon anti-dilution right
        		                           817,731 
          other non-cash income and expenses
        		                            
          proceeds from public offering of common stock, net of 2,123 issuance costs
        		                            
          proceeds from issuance of convertible promissory notes
        		                           0 
          proceeds from exercise of stock options, including early exercise
        		                           91,881 
          conversion of convertible promissory notes into common stock
        		                            
          issuance of common stock to biocon pursuant to certain anti-dilution rights
        		                            
          other non-cash expense
        		                          7,000  
          costs paid in connection with initial public offering
        		                            
          proceeds from issuance of unvested common stock
        		                            
          non-cash research license expense
        		                            
          proceeds from public offering of common stock, net of 2,123,106 issuance costs
        		                            
          proceeds from issuance of convertible promissory notes related party
        		                            
          proceeds from issuance of common stock
        		                            
          supplemental disclosures of noncash activities:
        		                            
          issuance of common stock to biocon for license
        		                            
          deferred initial public offering costs included in accounts payable and accrued expenses
        		                            
          supplemental disclosures of noncash activities: - sum